Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience.

Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Abstract Text:

Aaron Weiss,Joseph D Khoury,Fredric A Hoffer,Jianrong Wu,Catherine A Billups,Robert K Heck,Juan Quintana,Debbie Poe,Bhaskar N Rao,Najat C Daw,

BACKGROUND: Telangiectatic osteosarcoma (TOS) is a rare subtype of osteosarcoma (OS). The authors reviewed their experience with TOS to characterize its histologic, radiologic, and clinical features. METHODS: The authors reviewed records, pathology material, and imaging studies from all patients with TOS who were treated between 1978 and 2005 and compared their outcomes with the outcomes of patients with all other subtypes of high-grade osteosarcoma (OS). RESULTS: Among 323 patients with OS, 22 patients (6.8%) had TOS. Two additional patients who were treated in Chile on a recent OS trial were included. The median age at diagnosis of the 24 patients was 15.7 years. Four patients (17%) had metastatic disease, and 9 of 21 patients (43%) had pathologic fractures. Only 5 patients (who were treated after 1994) underwent limb-salvage surgery. Estimates of 5-year event-free survival (58.3% +/- 11.9%) and overall survival (66.8% +/- 11.6%) were similar to those for patients with other OS subtypes (P > or = .85). The absence of local disease progression and chemotherapy with > or =3 agents that were active against OS were correlated with improved outcome (P < or = .005). The presence of a pathologic fracture was not associated with surgery type or patient outcome. CONCLUSIONS: TOS was associated with a high rate of pathologic fracture. With multimodality therapy, the outcome of patients with TOS was similar to that of patients with other high-grade OS subtypes. The absence of local disease progression and chemotherapy with > or =3 active agents were associated with a favorable outcome.

Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Publishing Authors By Initials

A Weiss,JD Khoury,FA Hoffer,J Wu,CA Billups,RK Heck,J Quintana,D Poe,BN Rao,NC Daw,

For similar cardiovascular diseases: vascular diseases: telangiectasis research abstracts see: cardiovascular diseases: vascular diseases: telangiectasis research

PUBMED ID PMID:

MEDLINE DATE:

Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cancer

VOLUME: 109

Page Numbers: 1627-37

Journal Abbreviation: Cancer

ISSN: 0008-543X

DAY: 15

MONTH: Apr

YEAR: 2007

Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 374236

Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Keywords Mesh Terms:

KEYWORDS: Telangiectasis

MESH TERMS: pathology

Chemical & Substance for Abstract: Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience.

AFFILIATION: Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA23099

ACRONYM: CA

MEDLINETA: Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Telangiectatic osteosarcoma: the St Jude Children's Research Hospital's experience Related Publications

• Allergic reaction to quinestrol.
• Cerebral nocardiosis in a patient with NHL treated with rituximab.
• Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer.
• Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
• Disseminated Cryptococcosis in a Patient With Idiopathic CD4+ T-Lymphocytopenia.
• Dopamine: at the intersection of reward and action.
• Evidence for a nicotinic component to the actions of acetylcholine in cat visual cortex.
• Hereditary hemorrhagic telangiectasia with inherited thrombophilia.
• Human prolactin.
• Knee presentation.
• Lag effects in the impacts of mass coral bleaching on coral reef fish, fisheries, and ecosystems.
• Poststerilization mittelschmerz.
• Primary pleuropulmonary synovial sarcoma.
• Recurrent erythema nodosum of pregnancy.
• Telangiectatic osteosarcoma: the St. Jude Children's Research Hospital's experience.
• The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
• Transfer of complex frontline anticancer therapy to a developing country: The St. Jude osteosarcoma experience in Chile.
• Wilms' tumor.